GluCase is raising $750,000 with a minimum reservation of $5,000. Numbers displayed include non-binding reservations before investors are verified, signed, or closed.
GluCase is the world's first all-in-one smartphone case glucometer, syncable with other data and activity trackers, and offers coaching. By 2020, half of all US adults will be diabetic/prediabetic.
Hundreds of pre-order sales in fewer than 30 days (glucase.net)January, 2016
Commercialization partnership with OtterBox: #1 smartphone case in North AmericaJuly, 2016
Backed by Techstars, Sprint, Jumpstart Foundry, & Seamless IoTSeptember, 2016
In negotiations to close first B2B partnerships (estimated $10M+ annual recurring revenue)February, 2017
A recurring-revenue, monthly subscription for disposable supplies, mobile application, and dashboard.
AkibaH will initially target endocrinology and primary care practices where most newly diagnosed individuals receive their glucose meters and visit every three months to review their blood sugar.
We have partnered with OtterBox, the #1 selling case in North America. Our solution functions with their system which takes into account different phone models.
No, there is significant opportunity with or without reimbursement from big payers. For those that aren't covered, we match their typical out-of-pocket expense.
Regarding non-invasive technology, not only has it failed to make a viable medical product in the past 30 years, the latest set of companies utilizing this technology is making the weaker, non-clinical claim of being able to track calorie intake.
The white-labeled meter that we're integrating into our proprietary case system is already FDA cleared.